581 related articles for article (PubMed ID: 30061045)
41. Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows.
Roberts PJ; Kumarasamy V; Witkiewicz AK; Knudsen ES
Mol Cancer Ther; 2020 Aug; 19(8):1575-1588. PubMed ID: 32546660
[TBL] [Abstract][Full Text] [Related]
42. Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models.
Long F; He Y; Fu H; Li Y; Bao X; Wang Q; Wang Y; Xie C; Lou L
Cancer Sci; 2019 Apr; 110(4):1420-1430. PubMed ID: 30724426
[TBL] [Abstract][Full Text] [Related]
43. The transcriptome of CDK4/6 inhibition.
Knudsen ES; Witkiewicz AK
Aging (Albany NY); 2017 Aug; 9(8):1859-1860. PubMed ID: 28860413
[No Abstract] [Full Text] [Related]
44. Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity.
Jin D; Tran N; Thomas N; Tran DD
PLoS One; 2019; 14(10):e0223555. PubMed ID: 31600301
[TBL] [Abstract][Full Text] [Related]
45. Beyond the Cell Cycle: Enhancing the Immune Surveillance of Tumors Via CDK4/6 Inhibition.
Chaikovsky AC; Sage J
Mol Cancer Res; 2018 Oct; 16(10):1454-1457. PubMed ID: 29934327
[TBL] [Abstract][Full Text] [Related]
46. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.
Rader J; Russell MR; Hart LS; Nakazawa MS; Belcastro LT; Martinez D; Li Y; Carpenter EL; Attiyeh EF; Diskin SJ; Kim S; Parasuraman S; Caponigro G; Schnepp RW; Wood AC; Pawel B; Cole KA; Maris JM
Clin Cancer Res; 2013 Nov; 19(22):6173-82. PubMed ID: 24045179
[TBL] [Abstract][Full Text] [Related]
47. Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis.
Oh SJ; Cho H; Kim S; Noh KH; Song KH; Lee HJ; Woo SR; Kim S; Choi CH; Chung JY; Hewitt SM; Kim JH; Baek S; Lee KM; Yee C; Park HC; Kim TW
Cancer Res; 2018 May; 78(10):2638-2653. PubMed ID: 29437706
[TBL] [Abstract][Full Text] [Related]
48. Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens.
Kato S; Okamura R; Adashek JJ; Khalid N; Lee S; Nguyen V; Sicklick JK; Kurzrock R
JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33427211
[TBL] [Abstract][Full Text] [Related]
49. CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy.
Nardone V; Barbarino M; Angrisani A; Correale P; Pastina P; Cappabianca S; Reginelli A; Mutti L; Miracco C; Giannicola R; Giordano A; Pirtoli L
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445095
[TBL] [Abstract][Full Text] [Related]
50. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
51. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
[TBL] [Abstract][Full Text] [Related]
52. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
Wang L; Wang J; Blaser BW; Duchemin AM; Kusewitt DF; Liu T; Caligiuri MA; Briesewitz R
Blood; 2007 Sep; 110(6):2075-83. PubMed ID: 17537993
[TBL] [Abstract][Full Text] [Related]
53. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt.
Zhang J; Xu K; Liu P; Geng Y; Wang B; Gan W; Guo J; Wu F; Chin YR; Berrios C; Lien EC; Toker A; DeCaprio JA; Sicinski P; Wei W
Mol Cell; 2016 Jun; 62(6):929-942. PubMed ID: 27237051
[TBL] [Abstract][Full Text] [Related]
55. Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications.
Yousuf M; Alam M; Shamsi A; Khan P; Hasan GM; Rizwanul Haque QM; Hassan MI
Int J Biol Macromol; 2022 Oct; 218():394-408. PubMed ID: 35878668
[TBL] [Abstract][Full Text] [Related]
56. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
Scott SC; Lee SS; Abraham J
Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
[TBL] [Abstract][Full Text] [Related]
57. Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms.
Kim JY; Jayne LA; Bai Y; Feng MJHH; Clark MA; Chung S; W Christman J; Cianciolo RE; Pabla NS
Biochem Pharmacol; 2020 Jul; 177():113939. PubMed ID: 32229099
[TBL] [Abstract][Full Text] [Related]
58. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
[TBL] [Abstract][Full Text] [Related]
59. Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer.
Mills CC; Kolb EA; Sampson VB
Cancer Res; 2017 Dec; 77(23):6489-6498. PubMed ID: 29097609
[TBL] [Abstract][Full Text] [Related]
60. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.
VanArsdale T; Boshoff C; Arndt KT; Abraham RT
Clin Cancer Res; 2015 Jul; 21(13):2905-10. PubMed ID: 25941111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
